Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Remifentanil + lidocaine is a combination of two pharmaceutical agents commonly used in anesthesia and perioperative pain management. Remifentanil is an ultra-short-acting synthetic opioid analgesic that acts as a potent agonist at the µ-opioid receptor, providing rapid-onset and short-duration analgesia. It is primarily used for induction and maintenance of general anesthesia, conscious sedation, and postoperative pain control[1][4][6]. Lidocaine is a widely used local anesthetic with additional properties including suppression of cough reflexes, analgesia, anti-hyperalgesia, and anti-inflammatory effects[5]. When administered together intravenously during surgical procedures or intubation/extubation events, lidocaine can reduce the required dose of remifentanil to suppress airway reflexes such as coughing while also decreasing the risk of respiratory depression associated with higher opioid doses[5]. This combination leverages both central (remifentanil) and peripheral (lidocaine) mechanisms to optimize patient comfort and safety during anesthesia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on remifentanil + lidocaine.